Rohto Pharmaceutical Co., Ltd. announced that for the Fiscal Year Ending March 31, 2022, the company expects, net sales of ¥182,000 million, operating profit of ¥23,100 million and profit attributable to owner of parent of ¥17,100 million or ¥149.91 per share.